Nurix Therapeutics, Inc.'s revenue has grown 117% a year over three years, and grown 89% a year over five. Revenue growth, 3-year annual rate: +117% (Biotechnology median +21%). Revenue growth, 5-year rate: +89%, growth has picked up over the last three years. Years of annual history on file: 7, FY2019 to FY2025, as filed.

NRIXNurix Therapeutics, Inc.

Healthcare

$25.33+152% 1Y

$25.33

$9.8452 weeks$27.79

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +739% year on year, but earnings down −177% year on year and operating margin narrowing (−238.8 points).

1 good, 2 to watch

Revenue trend+739% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +89% a year.

Earnings trend−177% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction−238.8 points operating

Trailing-twelve-month operating margin, -762.5% now against -523.7% a year earlier.

All from SEC EDGAR, as of Aug 31, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearstop 1% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is NRIX growing?

Nurix Therapeutics, Inc.'s revenue has grown 117% a year over three years, and grown 89% a year over five.

+117%

Revenue growth, 3-year annual rate · Biotechnology median +21% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +89%
Revenue growth, 5-year rate · +117% over three · growth has picked up over the last three years
Years of annual history on file: 7
Years of annual history on file · FY2019 to FY2025, as filed

Details›